-
Professor Wang Jianxiang: Cohesive force, source of the future - the innovation road of Hergilensa cell injection The 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-06
Figure 6 Hergilencel clinical development planThird, the preliminary data of the Hergilencel clinical studyAbout 50%-60% of adult ALL patients will relapse or refractory to treatment, the prognosis of this part of patients is very poor, although new drugs have been approved for marketing in recent years, but the prognosis improvement is not significant, the overall survival is not significantly improved, only 4~7.
-
Research Express! Iberdomide in combination with dexamethasone in the treatment of advanced R/R MM is a new progress
Time of Update: 2023-01-06
Multiple myeloma (MM) is characterized by the persistence of minimal residual disease during combination therapy by patients, leading to multiple cycles of remission and recurrence. Each subsequent li
-
The original intention is like a torch, hard work is like sail, leukemia and lymphoma special session 1 focuses on the frontier The Harbin branch of the 2022 CSCO Academic Annual Conference
Time of Update: 2023-01-06
Click to read the original article to see more conference videosProfessor Zhang Huilai of Tianjin Medical University Cancer Hospital gave a report entitled "The New Era of Lymphoma Immunotherapy: Breakthroughs and Challenges in Immune Checkpoint Research" from multiple dimensions such as immune dysregulation mechanism and immunotherapy methods.
-
Iron deficiency anemia and thrombocytosis pair CP
Time of Update: 2023-01-06
SometimeYou met a child considering iron deficiency anemia in the outpatient clinic, but found that the platelet count on the blood routine report also increased significantly, could it be another blood disease?
-
Iron deficiency anemia and thrombocytosis pair CP
Time of Update: 2023-01-06
SometimeYou met a child considering iron deficiency anemia in the outpatient clinic, but found that the platelet count on the blood routine report also increased significantly, could it be another blood disease?
-
Professor Liu Peng from HEMA perspective: RWS in China has identified the benefits of anti-CD20 monoclonal antibody maintenance therapy, providing new evidence for the optimization of FL treatment
Time of Update: 2023-01-06
1Yimaitong: It is understood that your Chinese Academy of Medical Sciences Cancer Hospital Internal Medicine-Lymphoma Treatment Team conducted a real-world study (RWS) with more than 5 years of follow-up for the first time in the era of rituximab in the era of advanced FL in China, and explored the impact of anti-CD20 monoclonal antibody maintenance therapy on patients' treatment outcomes.
-
Focus on the frontier and help ASCT flourish - CSCO Autologous Transplantation Working Group 2022 Tour (Wuhan Station) ended perfectly
Time of Update: 2023-01-06
Big coffee gathers, based on clinical practice, sharing academic hot spots! On October 30, 2022, the CSCO Autologous Transplantation Working Group 2022 Tour (Wuhan Station), hosted by the Chinese Soci
-
Focus on the frontier and help ASCT flourish - CSCO Autologous Transplantation Working Group 2022 Tour (Wuhan Station) ended perfectly
Time of Update: 2023-01-06
Big coffee gathers, based on clinical practice, sharing academic hot spots! On October 30, 2022, the CSCO Autologous Transplantation Working Group 2022 Tour (Wuhan Station), hosted by the Chinese Soci
-
Professor Qiu Lin: Dynamic monitoring of mutant genes, NGS to help AML personalized precision treatment| the 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-06
Next-generation sequencing (NGS) plays an important role in the prognosis analysis, efficacy evaluation, recurrence prediction and detection of minimal residual disease (MRD) in acute myeloid leukemia
-
Professor Ying Zhitao: The road ahead is also bright, improve the efficacy of CAR-T, solve the dilemma of CAR-T cell therapy, and the 7th International Summit Forum on Anti-leukemia and Lymphoma is on the road
Time of Update: 2023-01-06
On the occasion of the "7th Anti-Leukemia and Lymphoma International Summit Forum and CSCO Leukemia & Lymphoma Expert Committee Tour - Harbin Station", Yimaitong is honored to invite Professor Ying Zhitao of Peking University Cancer Hospital to be interviewed to introduce the current status of CAR-T cell therapy in lymphoma treatment, and talk about the achievements and future exploration directions of the lymphoma department of Peking University Cancer Hospital (Beiwei).
-
Feifan Blood Cloud Classroom November Myeloma Literature Intensive Reading Workshop
Time of Update: 2023-01-06
discussThis study is the largest RRMM WGS data analysis to date (616 total patients) and provides the most comprehensive RRMM genome-wide analysis to date, identifying new RRMM driver genes through coding and noncoding region variants of the genome.
-
Feifan Blood Cloud Classroom November Myeloma Literature Intensive Reading Workshop
Time of Update: 2023-01-06
discussThis study is the largest RRMM WGS data analysis to date (616 total patients) and provides the most comprehensive RRMM genome-wide analysis to date, identifying new RRMM driver genes through coding and noncoding region variants of the genome.
-
Professor Li Fei: Seliniso rises to the challenge and breaks the dilemma of multiple myeloma recurrence and incurability!
Time of Update: 2023-01-06
The Guidelines for the Diagnosis and Treatment of Multiple Myeloma in China (2022 Revision)5 points out that 3-4 drugs containing proteasome inhibitors, immunomodulators, daratumumab and nuclear output protein inhibitor celinisol can be selected as much as possible, and salvage autologous hematopoietic stem cell transplantation (ASCT) can be performed if possible 。 BOSTON STUDY7 SHOWED THAT THE MEDIAN PFS IN THE CELINISO PLUS BORTEZOMIB AND DEXAMETHASONE (VD) GROUPS WAS SIGNIFICANTLY LONGER THAN IN THE BORTEZOMIB PLUS DEXAMETHASONE (VD) GROUP (PFS: 13.
-
Yi Shuo Blood New Time and Space Gathering Chinese and foreign forces, talking about multidisciplinary progress, MM International Exchange Conference was grandly held
Time of Update: 2023-01-06
The content is rich and rewarding, I hope that all colleagues, especially young doctors, will ponder this repeatedly and move forward firmly!At the end of the conference, Professor Chen Wenming, the chairman of the conference, concluded that the conference showed the considerable results of clinical trials, and then sublimated to real-world patient data statistics, and explained in detail the treatment strategies of MM and the development of high-quality real-world research through Sino-foreign exchanges and interdisciplinary sharing.
-
"Artificial red blood cells" are used in human trials for the first time! Or will revolutionize the treatment of patients with blood disorders!
Time of Update: 2023-01-06
The UK's National Health Service (NHS) has launched a clinical trial with research institutions such as the University of Bristol to inject laboratory-grown red blood cells into humans for the first time.
-
JCO(IF=51) Shanghai Jiao Tong University multi-unit cooperation, Academician Pei Zhengkang's team found that CAR-T therapy is safe and effective in the treatment of relapsed or refractory B acute lymphoblastic leukemia
Time of Update: 2023-01-06
iNatureIt is unclear whether combination therapy with CD19 and CD22 chimeric antigen receptor T cells leads to durable event-free survival in children with refractory disease or high-risk B acute lymp
-
Upcoming Conference On November 11, UCLI-CDE invited you to learn about the frontiers of innovative drug research and development
Time of Update: 2023-01-06
In order to further improve the diagnosis and treatment level of leukemia and lymphoma in China, Harbin Hematological Diseases is sponsored by the Chinese Society of Clinical Oncology (CSCO), CSCO Leu
-
Upcoming Conference On November 11, UCLI-CDE invited you to learn about the frontiers of innovative drug research and development
Time of Update: 2023-01-06
In order to further improve the diagnosis and treatment level of leukemia and lymphoma in China, Harbin Hematological Diseases is sponsored by the Chinese Society of Clinical Oncology (CSCO), CSCO Leu
-
Can autologous hematopoietic stem cell transplantation after first-line therapy prolong the survival of patients with stage II-IV peripheral T-cell lymphoma < 65 years of age?
Time of Update: 2023-01-06
Poke "Read Original" to see moreIn this large study, researchers observed a significant increase in OS rates in patients with advanced PTCL over the past 20 years, but the prognosis remains poor.
-
Can autologous hematopoietic stem cell transplantation after first-line therapy prolong the survival of patients with stage II-IV peripheral T-cell lymphoma < 65 years of age?
Time of Update: 2023-01-06
Poke "Read Original" to see moreIn this large study, researchers observed a significant increase in OS rates in patients with advanced PTCL over the past 20 years, but the prognosis remains poor.